To the Editor.—We read with great interest the letter from Woehlck et al.¹ and the accompanying response from Arrow Inc.,² (Reading, PA) concerning problems with removing the Arrow FlexTip epidural catheter. We wish to underline the importance of this topic with our own experience.

In a woman (65 yr, American Society of Anesthesiologists physical status III, 187 cm, 83 kg) a thoracic epidural catheter (T8 interspace, in place for 7 days) could not be removed despite multiple attempts, including replacing the patient in the position in which the catheter had been inserted. Unfortunately the plastic outer portion disrupted first and then the wire. After radiographic visualization, the remaining part of the disrupted catheter needed to be removed surgically. Both parts of the disrupted catheter were sent to Arrow Inc., for analysis. but no signs of failure of material could be detected.

In a 48-yr-old man (American Society of Anesthesiologists physical status I, 187 cm, 72 kg) a thoracic epidural catheter for arthroscopic surgery of the knee, was induced with the patient in the right lateral decubitus position. After the operation, multiple attempts to remove the catheter while the patient was in the lateral decubitus position were unsuccessful. Therefore, we turned the patient in the right lateral decubitus position, in which position the catheter originally had been inserted. During this maneuver, we observed that the catheter shifted around 2.5 cm within the skin across the back of the patient. After replacing the patient in the right lateral decubitus position the catheter could be removed without any problems.

In Reply.—We appreciate the correspondence from Drs. Hopf and Leischik elaborating on the difficulties of removing the Arrow (Reading, PA) FlexTip epidural catheter. In our patient,¹ as in the first patient described by Drs. Hopf and Leischik, the catheter could not be removed even when the patient was in the position in which the catheter was placed originally. For the other cases they described, it seems that placing the patient in the original position resulted in easier removal of the catheter than while the patient was in any other position. This may imply that compressive forces that exist when the catheter is in place between bony structures may be minimized when the patient is returned to the original insertion position. It also implies that greater friction forces exist with this catheter than with other types of catheters.

As Keim² noted, the FlexTip Plus is made from a very soft polyurethane material. When passed through the epidural needle, it is probable that little if any lateral force exists that would produce friction that could impair insertion, and the softness of the catheter may be a significant attribute. It is probable that considerable lateral force is applied to the catheter by tissue after the needle is withdrawn. One can speculate that the coefficient of friction may not correlate with the firmness of the catheter, and could potentially be greater with the Flex Tip catheter than with other types of catheters. This might be an important factor in the difficulty of removal. This seems to be an area that may prove to be a fruitful topic for further study. We agree with Drs. Hopf and Leischik that the difficulty of removal may be of considerable clinical importance and should result in appropriate labeling of the device.

Harvey J. Woehlck, M.D., Matthias Leischik, M.D. Abteilung für Anästhesie und Intensivmedizin, Langen, Germany. H-B.Hopf@t-online.de

References


(accepted for publication June 26, 2000.)
To the Editor:—We found the article by Gold et al.1 in the December 1999 issue of Anesthesiology, which described results with anesthesia-assisted rapid opioid detoxification (AROD) interesting. During the past decade, the practice of opioid detoxification during general anesthesia has become increasingly popular. Despite this, there is scant literature to document the advantages and disadvantages of this procedure. Therefore, Gold et al.1 provide valuable information about patient selection, the anesthetic techniques used, and the degree of residual symptoms observed after the procedure. They also present preliminary information regarding abstinence rates after AROD. The authors should be commended for providing this clinically useful information.

Unfortunately, the authors do not include in the abstract that 1 of the 20 patients died between 34 and 41 h after the end of the procedure. Not until near the end of the Results section of the body of this article is the death mentioned. Obviously, death is a terrible complication and a significant finding, particularly because this is an experimental procedure. Moreover, the authors state in the Results section of the abstract: “all 20 patients were successfully detoxified with no adverse events.” This is outrageously misleading; in the hands of these authors, AROD has a mortality rate of 5% within 48 h; however, it seemed that death was not directly the result of the administration of general anesthesia. Because of the absence of illicit drugs in the patient’s system at the time of death, death was in all likelihood related to effects of the precipitated withdrawal process. Therefore, Gold et al.1 provide valuable information about the procedure. Moreover, the authors state in the Results section of the abstract: “all 20 patients were successfully detoxified with no adverse events.” This is outrageously misleading; in the hands of these authors, AROD has a mortality rate of 5% within 48 h; however, it seemed that death was not directly the result of the administration of general anesthesia. Because of the absence of illicit drugs in the patient’s system at the time of death, death was in all likelihood related to effects of the precipitated withdrawal process.

We agree with the authors’ recommendation to provide continuous cardiac monitoring of AROD patients during their hospital stays. In a previous issue of Anesthesiology, Kienbaum et al.,2 reported profound increases in plasma epinephrine concentrations and cardiovascular stimulation during naloxone-precipitated opioid withdrawal during anesthesia. Even more recently, Allhoff et al.3 concluded that ultra-short opiate detoxification is associated with a risk of QT-interval prolongation and bradycardia. Furthermore, these effects could be related to hypokalemia or the use of clonidine during the procedure. Because of the increase in circulating catecholamines and the likelihood of fluid and electrolyte loss during precipitated withdrawal, there is certainly the potential for a significant arrhythmia after AROD. Therefore, we also advocate the use of continuous monitoring (telemetry and pulse oximetry) during a hospital stay for AROD. We are conducting the first National Institutes of Health-funded (Bethesda, Maryland) randomized trial that compares the safety and effectiveness of AROD with two alternative methods of opioid detoxification, and we incorporate this monitoring for all AROD patients. Again (although this omission is far less serious), in the Conclusion section of the abstract, the authors do not mention the potential need for increased monitoring.

We recognize that editorial considerations limit the material that can be included in an abstract; these omissions from the abstract, however, are serious. Today, computerized literature searches often yield little more than the abstract of an article. As a result, the most significant findings from a study must be included in the abstract of the article. We therefore respectfully ask the editors to publish a correction to the abstract of this article. In a study designed to evaluate a novel, experimental procedure, such as AROD, can there be a more significant finding than death?

*Robert A. Whittington, M.D., Eric D. Collins, M.D., Herbert D. Kleber, M.D. *Columbia University, New York, New York. raw9@columbia.edu

References

(Accepted for publication June 16, 2000.)

In Reply.—Dr. Whittington raises a valid point. The death of one patient after anesthesia-assisted rapid opioid detoxification is a significant event, and we clearly recognized it as such. However, his concern is over the decision to omit this information from the abstract and instead, to describe the patient’s death in the Results section of the manuscript. He also raises issue with our statement of “successful detoxification of 20 patients without adverse events.”

We gave serious thought to the construction of the abstract. We looked very closely at all the information available to determine the cause of death, but were unable to do so. Dr. Whittington believes that, because no illicit drugs were found in the patient’s blood, death was “in all likelihood” related to the effects of the procedure. Our conclusions were much less clear. We considered the patient’s history of hypertension and smoking as contributory to a possible myocardial infarction, and other causes of sudden death, for example, aneurysm or pulmonary embolus. We believe the abstract is not the place to speculate when information is not available.

Dr. Whittington mentions some well-known physiologic changes that can occur during some less widely used protocols, i.e., increased plasma catecholamine levels and prolonged QT intervals. The issue that is not well-known or perhaps not known at all is whether any of these changes persist into the postdetoxification period and, if so, for how long. The majority of patients undergoing the procedure are discharged to home the day after the procedure; therefore, detailed collection of physiologic data has not been possible. This patient met all discharge criteria within 24 h of the procedure.

Our protocol specifically addressed the hemodynamic changes of withdrawal, and we did not see changes in heart rate, blood pressure, or the electrocardiogram. This is not to say that these types of events could not occur, but we did not see them in this patient. Furthermore, we clearly mention the potential need for postprocedure monitoring in the Discussion section; therefore, his comment concerning this “omission” is in error. We are pleased to see that Dr. Whittington has received support for a study that incorporates this type of monitoring. We look forward to his results and plan on proceeding the same way in our own program.

Finally, we used currently accepted clinical criteria in determining the end point for detoxification. These criteria were applied after the patient had emerged from anesthesia and before the patient’s discharge from the postanesthesia care unit. We repeat our conclusion...
from the study that all 20 patients were successfully detoxified without adverse events. We clearly describe adverse events that occurred, such as nausea or diarrhea and the death of a patient, but all were encountered in the postdetoxification period while the patients were with the rehabilitation service. We have treated 41 patients, and there have been no other deaths in our program.

Current efforts are under way to more fully explore the deaths associated with anesthesia-assisted rapid opioid detoxification worldwide. We join other practitioners and researchers in anticipating the results of those studies. There is no reason to publish a correction to our abstract.

To the Editor—1 I congratulate Dr. Ueyama et al.1 for their work regarding the effects of crystalloid and colloid loading in parturients undergoing spinal anesthesia. However, the relevance of this work—and many other studies concerning fluid loading—to fetal well-being is not entirely clear. Studies consistently have shown a beneficial effect of volume loading on maternal blood pressure or the response to the induction of spinal or epidural anesthesia. Moreover, the importance of maternal blood pressure on the fetus is unclear. For example, our work has shown that changes in cardiac output produced by volume loading may correlate better with uterine blood flow than does blood pressure.2

Profuse hypotension clearly can compromise uterine perfusion, but the influence of lesser changes or of various interventions used to influence blood pressure is unknown. In our opinion, the issue of volume loading may be centered on the wrong parameters. A far better end point would be something such as uterine blood flow or perhaps umbilical blood flow. In the past, these could only be assessed in animals.3 However, Doppler methods now permit such measurements. In fact, the current availability of color Doppler makes it possible to measure not only flow velocities, but also absolute flow in selected vessels. To measure the effectiveness of therapeutic interventions in obstetric anesthesia practice, future studies should take advantage of this new technology, rather than being limited to parameters such as blood pressure, blood volume, and cardiac output.

References

In Reply—We thank Dr. Marcus for the interest in our work and the comments. In parturients with normal uteroplacental circulation, uterine blood flow is the major determinant of oxygen transport to the fetus. The increase in uterine blood flow after colloid preload suggested by Dr. Marcus is interesting. Our results suggested that colloid preload resulted in marked increases in maternal cardiac output without significant change in blood pressure. Therefore, the increase in uterine blood flow may be associated with an increase in maternal cardiac output.

Doppler ultrasonography is the most commonly used method to measure uterine blood flow in humans. The velocity of the blood flow is one of the representative parameters measured with Doppler ultrasonography. However, the reliability of the measurements is controversial because shape of the waveform is affected by many factors, such as maternal cardiac output, elasticity of the vessel wall, outflow impedance, and blood viscosity. Calculation of blood flow necessitates precise determination of mean velocity, angle of insonation, and vessel diameter. Although angle of the insonation and blood velocity are determined correctly, accurate measurement of small-vessel diameters, such as the diameter of a uterine artery, is difficult. It is also not clear whether the blood flow reflects the functional placental perfusion because some portion of blood flow is shunted to the myometrium. Therefore, extrapolation of measurements from the Doppler ultrasonographic method must be done with caution.

As Dr. Marcus pointed out, an understanding of the uteroplacental blood flow is essential in obstetric anesthesia practice. However, the goal of our anesthetic management is to maintain fetal oxygenation, not uterine artery blood flow. We think that, in the future, fetal oxygenation monitoring would show the effect of preloading on fetal oxygenation.

Hiroshi Ueyama, M.D., Osaka University Medical School, Suita, Osaka, Japan. ueyama@hp-op.med.osaka-u.ac.jp

References

(Accepted for publication June 16, 2000.)
To the Editor:—Ben-David et al. have shown the advantages of combined low-dose bupivacaine and fentanyl spinal anesthesia versus a "conventional" dose of 10 mg bupivacaine. The 90% incidence of hypotension in the 10-mg bupivacaine group is very high (one of the disadvantages of including a small number of patients). This could have been minimized if the authors had chosen a smaller dose for the control group. Biboulet et al. considered a dose of 5 mg intrathecal bupivacaine to be "too high" to limit the block to T10 in geriatric patients because of a 40% incidence of hypotension. Moreover, Ben-David et al. have shown that a dose of 7.5 mg bupivacaine can produce an acceptable block up to T8. Choosing a 10-mg dose as a control in this study that involved geriatric patients exacerbated the differences among the two groups.

The authors did not mention anything about the quality of motor block in the minidose bupivacaine group. A previous study with 5 mg bupivacaine showed that in nearly 80% of the patients a Bromage scale score of 2 or 3 was not achieved.

I wonder whether the incidence of hypotension could be further lowered if "unilateral" spinal were attempted. It has been shown that glucose-free bupivacaine is hypobaric and, in low doses, can be used to provide satisfactory unilateral block and hemodynamic stability.

In Reply:—Our finding of a 90% incidence of hypotension after single-dose ("conventional") spinal anesthesia in elderly patients is consistent with the high incidence of hypotension reported in the literature. Others have reported a 100% incidence of hypotension necessitating vasopressor treatment. Buggy et al. found a 75% incidence of systolic hypotension even with a volume loading of 500 ml hetastarch, 6%, plus 500 ml Hartmann's solution. The strong association of spinal hypotension with ST depression in this patient population is of consequence.

Our choice of a 10-mg dose of spinal bupivacaine was intended to represent conventional practice and not necessarily the lowest dose of bupivacaine. This choice was arbitrary and, I suspect, underestimates the dosing used by many of our colleagues. The important point, however, is that, rather than treat hypotension, one can avoid it by using a low-dose local anesthetic plus an opiate spinal technique.

It is true that this technique provides a "nociceptive block" and does not provide a profound motor block. Certainly, there are surgeries in which the need for an intense motor block would necessitate higher doses of local anesthetic if one is to use spinal anesthesia. Likewise, there are surgeries (e.g., ambulatory) in which the absence of a profound motor block may be advantageous.

Our article did not intend to suggest that there is no other way to reduce the hypotension of spinal anesthesia. Titrated dosing with continuous spinal anesthesia is fairly effective in this regard, but it is my impression that many practitioners prefer the speed and simplicity of a single-shot technique. Although unilateral spinal anesthesia might offer greater hemodynamic stability than bilateral blockade, at best it is impractical (time-consuming) when surgery is to be performed with the patient in the supine position.

Bruce Ben-David, M.D., Allegheny General Hospital, Pittsburgh, Pennsylvania. bbendavid@mindspring.com

References


(Accepted for publication May 24, 2000.)

To the Editor:—Contrary to the statement in the letter by Adnet et al., figure 1 does not show a patient in the sniffing position. The sniffing position necessitates approximately 30–35° of flexion of the neck axis on the chest axis. Placing a patient’s head on a pillow is irrelevant if it does not achieve this end point. In figure 1 of the letter by Adnet et al., the neck seems to be flexed on the chest by only 5°. If the neck had been flexed on the chest by approximately 30–35°, the laryngeal axis would be almost identical to the pharyngeal axis, and the laryngeal and pharyngeal axes would be much closer to the oral axis. In addition, flexion of the neck on the chest might have permitted a slightly greater

Patient in “Sniffing Position”
degree of extension of the head axis on the neck axis, thereby further bringing the laryngeal, pharyngeal, and oral axes into alignment. I do not believe that figure 1 of the letter by Adnet et al. shows the patient in sniffing position.

Jonathan L. Benumof, M.D., University of California San Diego Medical Center, San Diego, California. jbenumof@ucsd.edu

Reference
In Reply—We agree with Professor Benumof that the angle of flexion of the neck shown on the radiograph was not exactly 30–35° from the horizontal axis. This radiograph was obtained while the patient was in standard position for intubation, with a cushion under the head as routinely performed in our operating room. However, we are not sure that the angle was 5°, as stipulated by Professor Benumof. Professor Benumof stated that the snifing position necessitates 30–35° of flexion of the neck axis on the chest. This was established by Horton et al.¹ These angles were defined between (1) the neck axis (defined by two landmarks: anterior portion of the cricoid and the lowermost depth palpable in the sternal notch) and (2) the horizontal axis.¹ Our radiography was performed with use of a portable X-ray machine; therefore, it is uncertain that the bottom of the radiograph corresponds to the horizontal axis. Moreover, because the two landmarks described by Horton et al.¹ are not visible in the radiograph, it is difficult to measure the angle of the neck flexion. We also disagree with Professor Benumof in establishing a relation between the degree of neck flexion (or extension of the head) and the alignment of the oral, pharyngeal, and laryngeal axes. This relation has never been shown. The relation between angle of neck flexion (or head extension) and alignment of the three axes (oral, pharyngeal, and laryngeal) has never been investigated scientifically to our knowledge. The figure reproduced in the textbook by Benumof² shows a patient in the sniffing position with the hard palate (i.e., oral axis) in line with the trachea; this alignment is almost impossible to attain in an anatomically normal patient, whatever the angle of neck flexion. The most important point is that, in the classic article by Bannister et al.,² this anatomic error was described because the figure is not true to the radiograph. Nevertheless, this figure has found its way into the anesthesiology literature.

We thank Dr. Hirsch and Dr. Smith for their interesting historical contribution. We can credit Dr. Kirstein as the first author who described atlantooccipital extension for direct laryngoscopy. However, Chevalier Jackson, in 1914, was the first who described clearly this maneuver for laryngoscopy to intubate a patient during anesthesia. The three-axis alignment theory was described not by Chevalier Jackson, but by Bannister in 1944.³ For the sake of completeness, the name “snifing position” comes from the Magill¹ article (in 1936) in which he described the optimal head position for laryngoscopy:

. . . The head itself is slightly extended on the atlas, so that the mandible is approximately at right angles to the table. When he wishes to sniff the air, a man in the normal erect posture instinctively and unconsciously takes this attitude . . . .

Frederic Adnet, M.D., Ph.D., Hopital Avicenne, Bobigny, France. frederic.adnet@avc.ap-hop-paris.fr

References


(Accepted for publication June 1, 2000.)

Epinephrine Plasma Levels Also Vary at Similar Infused Doses

To the Editor—We read with interest the study by MacGregor et al.¹ which showed that markedly different dopamine plasma levels may result from similar infusion rates in a homogenous population. Their results bear considerable similarity to a study we performed with epinephrine infusions at a time when arrhythmogenicity of anesthetics was a major concern. We identified that clearance of epinephrine and cardiac output were markedly and variably enhanced as much as 45 min after a large but brief epinephrine infusion in a canine model; however, arrhythmias tended to occur at similar plasma levels. Presumably because of this difference in cardiac output and clearance of epinephrine, different infusion rates were necessary to produce similar plasma levels of epinephrine; however, the range was not as dramatic as those determined by MacGregor et al.¹ with dopamine. Because dopamine and epinephrine both stimulate a multitude of catecholamine receptors, some of which have opposing hemodynamic effects, one should not find these results surprising. The phenomenon of attaining markedly different plasma levels for a particular infusion rate may be a property shared by catecholamines that stimulate multiple adrenoceptors. The results may be even more variable when subjected to interactions with α- and β-adrenoceptor blocking drugs, which may alter the effects of these catecholamines on circulation and ultimately on their own clearance.

Harvey J. Wochlick, M.D., Froedtert Memorial Lutheran Hospital, Milwaukee, Wisconsin. hwochlick@mcw.edu

References


(Accepted for publication June 26, 2000.)
Preemptive Analgesia: What Does It Really Mean?

To the Editor—I read with interest the article by Motamed et al. in the February issue of Anesthesiology, and agree with their finding that intravenously administered morphine-6-glucuronide (M-6-G) lacks analgesic effect. However, I am troubled by their conclusion (reflected in the title) that preemptive M-6-G is not an effective analgesic. Their methods indicate that at the beginning of skin closure, patients received intravenous morphine sulfate, M-6-G, or saline. The use of the word “preemptive” in this regard is wrong because the analgesics were administered after the surgical incision and because they were not maintained postoperatively.

The goal of preemptive analgesia is to prevent the establishment of central sensitization, which then amplifies postoperative pain. Postoperative central sensitization usually has a reduced effect because central sensitization has already been established. Carr cautions against the routine use of the word preemptive. He states that preemptive refers to measures that prevent sensitization to cells within the spinal cord dorsal horn and that preemptive analgesia by definition must be accomplished before the onset of nociception. Central hypersensitivity may develop despite the use of analgesia before a noxious stimulus. This may happen if the analgesia is inadequate to prevent central sensitization or if the analgesia is only provided before the stimulus. Postinjury hypersensitivity develops secondary to inflammatory changes that occur as a result of an injury and can also lead to central sensitization.

In summary, preemptive analgesia must occur before the injury, must be adequate to prevent central sensitization, and must be maintained postoperatively to prevent the inflammatory changes associated with postinjury hypersensitivity.

David L. Hepner, M.D., Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts. dhepner@zeus.bwh.harvard.edu

References


(Accepted for publication June 26, 2000.)